跳至主要内容
临床试验/ACTRN12610000219088
ACTRN12610000219088终止4 期

The effects of metformin on the LKB1/AMP-activated protein kinase (AMPK) pathway in breast tissue from women scheduled for reduction mammoplasty, a pilot study

Monash University0 个研究点目标入组 20 人开始时间: 2010年3月17日最近更新:
适应症

试验速览

阶段
4 期
状态
终止
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Open (masking not used)

入排标准

年龄范围
38 Years 至 60 Years(—)
性别
Female

入选标准

  • a) who are aged between 38 and 60 years
  • b) who are attending a breast surgeon and are scheduled to have a reduction mammoplasty
  • c) who have provided informed consent

排除标准

  • 1. Women with any of the following:
  • a) Use of any systemic hormones in the last 6 months;
  • b) serious endocrine disorder with systemic disease;
  • c) alcohol consumption greater than 3 standard drinks per day;
  • d) known acute or chronic liver disease;
  • e) cardiac failure requiring medication
  • f) known renal disease
  • g) chronic hypoxic lung disease
  • e) type 2 or insulin dependent diabetes mellitus or use of an oral hypoglycemic agent.
  • 2. Women who, in the opinion of the investigator, are a poor medical or psychiatric risk for treatment in a research protocol.
  • 3. Women who have participated in a medical or surgical research protocol in the preceding 28 days.

研究者

相似试验